Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors

Microbes and Infection

Volumn 8, Issue 7, 2006, Pages 1783-1789

  Fuse, Takayuki ^a   Watanabe, Ken ^a   Kitazato, Kaio ^a   Kobayashi, Nobuyuki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cytotoxicity; HIV 1 protease; Mammalian cell based system; Screening; Tet off system

Indexed keywords

BENZYLSULFONYL FLUORIDE; CHIMERIC PROTEIN; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; NELFINAVIR; PEPSTATIN; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; EMBRYO; ENZYME INDUCTION; FLUORESCENCE; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE; DOXYCYCLINE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; RECOMBINANT FUSION PROTEINS; SAQUINAVIR; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746411430     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.02.016     Document Type: Article

References (29)

1. O'Brien W.A., Hartigan P.M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberkoff M.S., and Hamilton J.D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans affairs cooperative study group on AIDS. N. Engl. J. Med. 334 (1996) 426-431
2. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 338 (1998) 853-860
3. Vlahov D., Galai N., Safaeian M., Galea S., Kirk G.D., Lucas G.M., and Sterling T.R. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am. J. Epidemiol. 161 (2005) 999-1012
4. Cote H.C., Brumme Z.L., and Harrigan P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75 (2001) 589-594
5. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., and Shafer R.W. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77 (2003) 4836-4847
6. Kantor R., Fessel W.J., Zolopa A.R., Israelski D., Shulman N., Montoya J.G., Harbour M., Schapiro J.M., and Shafer R.W. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob. Agents Chemother. 46 (2002) 1086-1092
7. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., Cullinan A.B., Stuver C.M., Byrn R.A., and Livingston D.J. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69 (1995) 5228-5235
8. Speck R.R., Flexner C., Tian C.J., and Yu X.F. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-Pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob. Agents Chemother. 44 (2000) 1397-1403
9. Louis J.M., Wondrak E.M., Kimmel A.R., Wingfield P.T., and Nashed N.T. Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism. J. Biol. Chem. 274 (1999) 23437-23442
10. Ishima R., Ghirlando R., Tozser J., Gronenborn A.M., Torchia D.A., and Louis J.M. Folded monomer of HIV-1 protease. J. Biol. Chem. 276 (2001) 49110-49116
11. Molla A., Vasavanonda S., Kumar G., Sham H.L., Johnson M., Grabowski B., Denissen J.F., Kohlbrenner W., Plattner J.J., Leonard J.M., Norbeck D.W., and Kempf D.J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250 (1998) 255-262
12. Krausslich H.G., Ingraham R.H., Skoog M.T., Wimmer E., Pallai P.V., and Carter C.A. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 807-811
13. Hu K., Clement J.F., Abrahamyan L., Strebel K., Bouvier M., Kleiman L., and Mouland A.J. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J. Virol. Methods 128 (2005) 93-103
14. Lindsten K., Uhlikova T., Konvalinka J., Masucci M.G., and Dantuma N.P. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob. Agents Chemother. 45 (2001) 2616-2622
15. Cheng T.J., Brik A., Wong C.H., and Kan C.C. Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli. Antimicrob. Agents Chemother. 48 (2004) 2437-2447
16. Tan A.S., and Berridge M.V. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J. Immunol. Methods 238 (2000) 59-68
17. Blanco R., Carrasco L., and Ventoso I. Cell killing by HIV-1 protease. J. Biol. Chem. 278 (2003) 1086-1093
18. Strack P.R., Frey M.W., Rizzo C.J., Cordova B., George H.J., Meade R., Ho S.P., Corman J., Tritch R., and Korant B.D. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9571-9576
19. Ventoso I., Navarro J., Munoz M.A., and Carrasco L. Involvement of HIV-1 protease in virus-induced cell killing. Antiviral Res. 66 (2005) 47-55
20. Wan M., and Loh B.N. Expression and purification of active form of HIV-1 protease from E. coli. Biochem. Mol. Biol. Int. 35 (1995) 899-912
21. Nie Z., Phenix B.N., Lum J.J., Alam A., Lynch D.H., Beckett B., Krammer P.H., Sekaly R.P., and Badley A.D. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ. 9 (2002) 1172-1184
22. Shoeman R.L., Hartig R., Hauses C., and Traub P. Organization of focal adhesion plaques is disrupted by action of the HIV-1 protease. Cell Biol. Int. 26 (2002) 529-539
23. Shoeman R.L., Honer B., Stoller T.J., Kesselmeier C., Miedel M.C., Traub P., and Graves M.C. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 6336-6340
24. Adams L.D., Tomasselli A.G., Robbins P., Moss B., and Heinrikson R.L. HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. AIDS Res. Hum. Retroviruses 8 (1992) 291-295
25. Wallin M., Deinum J., Goobar L., and Danielson U.H. Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases. J. Gen. Virol. 71 (1990) 1985-1991
26. Wozniak M.A., Modzelewska K., Kwong L., and Keely P.J. Focal adhesion regulation of cell behavior. Biochim. Biophys. Acta. 1692 (2004) 103-119
27. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84 (1996) 345-357
28. Sanchez-Madrid F., and del Pozo M.A. Leukocyte polarization in cell migration and immune interactions. EMBO J. 18 (1999) 501-511
29. Bodary S.C., and McLean J.W. The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J. Biol. Chem. 265 (1990) 5938-5941